The FDA needs to set standards for using artificial intelligence in drug development
Author
Charles K. Fisher
Published
November 7, 2019
Opinion: Poorly constructed AI algorithms for drug discovery and testing have the potential to cause harm. The FDA should play an important role in ensuring that AI-based drug development tools meet appropriate standards.
A fascinating approach to the problem of how to make clinical trials more efficient, and understand more about what may be possible with more and better patient data.
